Skip to main content

Table 4 Uptake-rate of the different products according to population and year of the analysis

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

  Year 1 Year 2 Year 3
Paediatrics
 rFVIIIFc 10% 15% 20%
 Advate® 27% 25.5% 24%
 Kogenate® 26.1% 24.7% 23.2%
 Refacto® 20.7% 19.6% 18.4%
 Helixate® 15.3% 14.5% 13.6%
 Recombinate® 0.9% 0.9% 0.8%
 Plasma-derived products
Adults
 rFVIIIFc 10% 15% 20%
 Advate® 21.6% 20.4% 19.2%
 Kogenate® 20.7% 19.6% 18.4%
 Refacto® 16.2% 15.3% 14.4%
 Helixate® 11.7% 11.1% 10.4%
 Recombinate® 0.9% 0.9% 0.8%
 Plasma-derived products 18.9% 17.9% 16.8%
\